Literature DB >> 23826696

3D microcarrier system for efficient differentiation of human pluripotent stem cells into hematopoietic cells without feeders and serum [corrected].

Shi-Jiang Lu1, Tim Kelley, Qiang Feng, Allen Chen, Shaul Reuveny, Robert Lanza, Steve K W Oh.   

Abstract

BACKGROUND: Human embryonic stem cells (hESCs) have been derived and maintained on mouse embryonic fibroblast feeders to keep their undifferentiated status. To realize their clinical potential, a feeder-free and scalable system for large scale production of hESCs and their differentiated derivatives is required. MATERIALS &
METHODS: hESCs were cultured and passaged on serum/feeder-free 3D microcarriers for five passages. For embryoid body (EB) formation and hemangioblast differentiation, the medium for 3D microcarriers was directly switched to EB medium.
RESULTS: hESCs on 3D microcarriers maintained pluripotency and formed EBs, which were ten-times more efficient than hESCs cultured under 2D feeder-free conditions (0.11 ± 0.03 EB cells/hESC input 2D vs 1.19 ± 0.32 EB cells/hESC input 3D). After replating, EB cells from 3D culture readily developed into hemangioblasts with the potential to differentiate into hematopoietic and endothelial cells. Furthermore, this 3D system can also be adapted to human induced pluripotent stem cells, which generate functional hemangioblasts with high efficiency.
CONCLUSION: This 3D serum- and stromal-free microcarrier system is important for future clinical applications, with the potential of developing to a GMP-compatible scalable system.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23826696     DOI: 10.2217/rme.13.36

Source DB:  PubMed          Journal:  Regen Med        ISSN: 1746-0751            Impact factor:   3.806


  8 in total

Review 1.  Dendritic cells derived from pluripotent stem cells: Potential of large scale production.

Authors:  Yan Li; Meimei Liu; Shang-Tian Yang
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

Review 2.  Vascular diseases await translation of blood vessels engineered from stem cells.

Authors:  Rekha Samuel; Dan G Duda; Dai Fukumura; Rakesh K Jain
Journal:  Sci Transl Med       Date:  2015-10-14       Impact factor: 17.956

3.  Improved erythroid differentiation of multiple human pluripotent stem cell lines in microcarrier culture by modulation of Wnt/β-Catenin signaling.

Authors:  Jaichandran Sivalingam; Hong Yu Chen; Bin-Xia Yang; Zhong Ri Lim; Alan Tin Lun Lam; Tsung Liang Woo; Allen Kuan-Liang Chen; Shaul Reuveny; Yuin-Han Loh; Steve Kah-Weng Oh
Journal:  Haematologica       Date:  2018-03-08       Impact factor: 9.941

Review 4.  The Opportunities and Challenges regarding Induced Platelets from Human Pluripotent Stem Cells.

Authors:  Meng-Xue Xu; Li-Ping Liu; Yu-Mei Li; Yun-Wen Zheng
Journal:  Stem Cells Int       Date:  2021-05-01       Impact factor: 5.443

5.  Scalable generation of universal platelets from human induced pluripotent stem cells.

Authors:  Qiang Feng; Namrata Shabrani; Jonathan N Thon; Hongguang Huo; Austin Thiel; Kellie R Machlus; Kyungho Kim; Julie Brooks; Feng Li; Chenmei Luo; Erin A Kimbrel; Jiwu Wang; Kwang-Soo Kim; Joseph Italiano; Jaehyung Cho; Shi-Jiang Lu; Robert Lanza
Journal:  Stem Cell Reports       Date:  2014-10-16       Impact factor: 7.765

Review 6.  Human pluripotent stem cell-derived products: advances towards robust, scalable and cost-effective manufacturing strategies.

Authors:  Michael J Jenkins; Suzanne S Farid
Journal:  Biotechnol J       Date:  2014-11-19       Impact factor: 4.677

Review 7.  Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing.

Authors:  Dito Anurogo; Nova Yuli Prasetyo Budi; Mai-Huong Thi Ngo; Yen-Hua Huang; Jeanne Adiwinata Pawitan
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

8.  Systematic microcarrier screening and agitated culture conditions improves human mesenchymal stem cell yield in bioreactors.

Authors:  Qasim A Rafiq; Karen Coopman; Alvin W Nienow; Christopher J Hewitt
Journal:  Biotechnol J       Date:  2016-02-29       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.